Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)

Sofia Ramiro, Robert B.M. Landewé, Désirée Van Der Heijde, Alexandre Sepriano, Oliver Fitzgerald, Mikkel Ostergaard, Joanne Homik, Ori Elkayam, J. Carter Thorne, Margaret Larche, Gianfranco Ferraciolli, Marina Backhaus, Gilles Boire, Bernard Combe, Thierry Schaeverbeke, Alain Saraux, Maxime Dougados, Maurizio Rossini, Marcello Govoni, Luigi SinigagliaAlain G. Cantagrel, Cornelia F. Allaart, Cheryl Barnabe, Clifton O. Bingham, Paul P. Tak, Dirkjan Van Schaardenburg, Hilde Berner Hammer, Rana Dadashova, Edna Hutchings, Joel Paschke, Walter P. Maksymowych

Research output: Contribution to journalArticle

Abstract

Objectives To investigate whether following a treat-to-target (T2T)-strategy in daily clinical practice leads to more patients with rheumatoid arthritis (RA) meeting the remission target. Methods RA patients from 10 countries starting/changing conventional synthetic or biological disease-modifying anti-rheumatic drugs were assessed for disease activity every 3 months for 2 years (RA BIODAM (BIOmarkers of joint DAMage) cohort). Per visit was decided whether a patient was treated according to a T2T-strategy with 44-joint disease activity score (DAS44) remission (DAS44 <1.6) as the target. Sustained T2T was defined as T2T followed in ≥2 consecutive visits. The main outcome was the achievement of DAS44 remission at the subsequent 3-month visit. Other outcomes were remission according to 28-joint disease activity score-erythrocyte sedimentation rate (DAS28-ESR), Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean definitions. The association between T2T and remission was tested in generalised estimating equations models. Results In total 4356 visits of 571 patients (mean (SD) age: 56 (13) years, 78% female) were included. Appropriate application of T2T was found in 59% of the visits. T2T (vs no T2T) did not yield a higher likelihood of DAS44 remission 3 months later (OR (95% CI): 1.03 (0.92 to 1.16)), but sustained T2T resulted in an increased likelihood of achieving DAS44 remission (OR: 1.19 (1.03 to 1.39)). Similar results were seen with DAS28-ESR remission. For more stringent definitions (CDAI, SDAI and ACR/EULAR Boolean remission), T2T was consistently positively associated with remission (OR range: 1.16 to 1.29), and sustained T2T had a more pronounced effect on remission (OR range: 1.49 to 1.52). Conclusion In daily clinical practice, the correct application of a T2T-strategy (especially sustained T2T) in patients with RA leads to higher rates of remission.

Original languageEnglish (US)
Pages (from-to)453-459
Number of pages7
JournalAnnals of the rheumatic diseases
Volume79
Issue number4
DOIs
StatePublished - Apr 1 2020

Keywords

  • remission
  • rheumatoid arthritis
  • treat-to-target

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)'. Together they form a unique fingerprint.

  • Cite this

    Ramiro, S., Landewé, R. B. M., Van Der Heijde, D., Sepriano, A., Fitzgerald, O., Ostergaard, M., Homik, J., Elkayam, O., Thorne, J. C., Larche, M., Ferraciolli, G., Backhaus, M., Boire, G., Combe, B., Schaeverbeke, T., Saraux, A., Dougados, M., Rossini, M., Govoni, M., ... Maksymowych, W. P. (2020). Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). Annals of the rheumatic diseases, 79(4), 453-459. https://doi.org/10.1136/annrheumdis-2019-216819